-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
Search results for: “patient perspective”
-
Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer With EGFR-Activating Mutations
By Julien Mazieres, MD, PhD Posted: October 2017 The standard of care for patients postresection for lung cancer is adjuvant chemotherapy, usually a platinum-based regimen.1 The deciphering of lung oncogenesis has led to the routine use of targeted therapy in metastatic lung cancer but, to date, the use of these agents in the adjuvant setting…
-
IASLC Leader Elected President of ESMO for 2020–2021: Solange Peters, MD, PhD
Posted: October 2017 The European Society for Medical Oncology (ESMO) has elected an emerging leader in thoracic oncology—and an IASLC board member—to lead the organization in 2020–2021. ESMO President- Elect Solange Peters, MD, PhD, is head of the medical oncology service and chair of thoracic oncology in the Oncology Department at the Centre Hospitalier Universitaire…
-
NCI Corner – Interview with Jeff Abrams
NCI Helping to Save Lives and Improve Cancer Survival Rates Scientific data from clinical trials are essential for evaluating new cancer treatments and setting new standards of care for patients. The National Cancer Institute (NCI) has supported clinical trials for over 50 years through the Cooperative Group Program, which has produced many important improvements in…
-
In Speech to Agency, New FDA Commissioner Highlights Anti-Smoking Efforts
By Erik T. MacLaren, PhD On May 11, 2017, Scott Gottlieb, MD, was sworn in as the 23rd Commissioner of Food and Drugs of the US Food and Drug Administration (FDA). Dr. Gottlieb previously served as Deputy Commissioner for Medical and Scientific Affairs at the FDA, and his background includes experience in medicine, medical policy,…
-
Q&A with Benjamin Solomon, MBBS, PhD, FRACP
Please give us a global perspective on the results of global ALEX. Will alectinib definitively displace crizotinib or ceritinib as the first-line treatment for ALK-rearranged non-small cell lung cancer (NSCLC)? The rapid pace of development of ALKtargeted therapies in NSCLC in the last decade has transformed outcomes for patients with ALK-rearranged NSCLC. Crizotinib, the first…
-
NCI Corner – Interview with Matthew Holderfield, PhD
Posted: June 2017 NCI to Team Up with Cancer Research UK and the Cancer Research Technology Pioneer Fund on RAS Research On April 19, 2017, Cancer Research UK (CRUK) and the Cancer Research Technology (CRT) Pioneer Fund announced a commitment of £2.5 million, or about $3.2 million, for a collaboration with the National Cancer Institute…
-
2017 ASCO Annual Meeting
Posted: June 2017 By Erik J. MacLaren, PhD The Annual Meeting of the American Society of Clinical Oncology (ASCO) is taking place June 2–6 in Chicago, Illinois, and over 5,000 abstracts have been accepted for presentation at the meeting or for online release. The theme of this year’s meeting is Making a Difference in Cancer…
-
FDA Corner – Interview with Commander Jason Humbert
Posted: June 2017 FDA Warns of Fraudulent Cancer Drugs On April 25, 2017, the US Food and Drug Administration (FDA) issued warning letters to 14 companies regarding more than 65 products being marketed with unproven or fraudulent claims. The products identified included pills, topical creams, ointments, oils, drops, syrups, teas, and a thermography device.1 The…
-
European Perspective on Molecular Testing
Posted: June 2017 By Νiki Karachaliou, MD, PhD The identification of oncogenic driver alterations in non-small cell lung cancer (NSCLC), such as EGFR mutations and ALK rearrangements, each of which confers sensitivity to small tyrosine kinase inhibitors, has made EGFR and ALK testing a necessity in routine molecular pathologic diagnosis. Furthermore, next-generation sequencing (NGS) studies…
-
IASLC International Mentorship Program Boosts Early Careers, Fosters International Collaboration
Posted: April 2017 By Keightley Amen, BA, ELS To help ensure that high-quality thoracic oncology care is available throughout the world and well into the future, the IASLC offers an International Mentorship Program to support early-career physicians and researchers from economically developing countries. The competitive program provides each winner with a full scholarship to the…
View ILCN Archives
Provider Resources
Popular Articles